Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines

/in

– 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding – Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials COVENTRY, England, Jan. 8, 2026 /PRNewswire/ — NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, […]

Read more

STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications

/in

8 January 2026, Cambridge, UK, and San Diego, US: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida Biosciences Inc. (AlidaBio), a company at the forefront of epitranscriptomics and RNA modification analysis. STORM will utilize AlidaBio’s advanced EpiPlex® and EpiScout® next-generation sequencing […]

Read more

ViCentra Expands Financing to $98 Million to Accelerate European Commercialization and Ready Next Generation Kaleido Insulin Patch Pump System for U.S. Access

/in

Secures an additional $13 million, bringing the total to $98 million with new investments from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, plus increased support from Innovation Industries Strengthens manufacturing scale-up and commercial operations in Germany, the Netherlands, and France, and advances U.S. market preparation Validates ViCentra’s strategy and team, […]

Read more

TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman

/in

TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman Groundbreaking thymus-rejuvenating biologics are designed to restore immune function and promote lasting immune health throughout all stages of life Basel, Switzerland, January 8, 2026 – TECregen, a biotechnology company pioneering thymus regeneration, today announced the successful completion of a […]

Read more

Lonza’s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next‑Generation Bispecific ADCs

/in

Multi-target license agreement grants Sidewinder access to Lonza’s clinically validated ADC platform Sidewinder’s pipeline of precision bispecific ADCs combined with Lonza’s clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications Amsterdam, The Netherlands, and San Diego, CA, 7 January 2026 — Synaffix B.V. […]

Read more